pharmaphorum

APRIL 27, 2022

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic breast cancer. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on.

Sales 59

Sales Drugs Antibody Licensing 59

pharmaphorum

DECEMBER 23, 2021

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The post FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag appeared first on. Daiichi Sankyo and AZ are close collaborators in the ADC arena.

Drugs 72

Drugs Antibody Clinical Trials Clinical Trials 72

The Pharma Data

MAY 4, 2021

q4default.bwalignc { text-align: center; list-style-position: inside }.q4default.bwalignl q4default.bwalignr { text-align: right; list-style-position: inside }.q4default.bwblockalignl Lorbrena is now indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test. –*/. <!–*/.q4default.bwalignc

Vaccination 40

Vaccination Vaccine Production Sales 40